Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): Subgroup analysis of a Phase 4 open-label randomized trial

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

Premixed insulins are recommended starter insulins in Chinese patients after oral antihyperglycemic medication (OAM) failure.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Patients were randomized in a ratio of 1: 1 to LM25 (n = 80) or LM50 (n = 76).

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Being open-label, the Insulin Lispro study did not mask who received what.

The Insulin Lispro group and the comparison group ran side by side rather than switching.

A mixed-effects model with repeated measures was used to analyze continuous variables.

The Cochran-Mantel-Haenszel test with stratification factor was used to analyze categorical variables.

What Was Measured

Topics PubMed links to this paper include Asian People, Blood Glucose, China, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents and Insulin Lispro.

Author keywords: mixed insulins, postprandial hyperglycemia, 中国, 糖化血红蛋白, 糖尿病 and 预混胰岛素.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Insulin Lispro.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Journal of diabetes), a journal based in Australia.

More context: the Insulin Lispro compound page, all human trials.